For decades, manufacturing was viewed as execution.
A necessary step in bringing a product to market—but not a strategic driver.
Decisions were made upstream.
Manufacturing followed.
That model no longer holds.
Today, manufacturing determines outcomes that were once considered separate:
- Speed to market
- Regulatory success
- Product quality
- Cost structure
Delays in manufacturing are no longer operational issues.
They are business risks.
A failed batch is not just a deviation.
It is a delay in supply.
A missed commitment.
A potential regulatory concern.
The complexity of modern therapies has only amplified this shift.
Processes are more sensitive.
Variability is less forgiving.
Scale-up is more challenging.
And the margin for error is smaller.
Organizations that recognize this have begun to reposition manufacturing.
Not as a downstream function—but as a strategic capability.
They invest earlier.
They integrate manufacturing into development decisions.
They treat operational readiness as critical to success.
Those that do not are finding themselves constrained.
By capacity.
By performance.
By systems that were never designed for today’s demands.
Manufacturing is no longer where execution happens.
It is where strategy becomes reality.
And in many cases—it is where success is decided.
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
